Lilly Seaport Innovation Center Opens
Advancing Genetic Medicines Research and Development
Eli Lilly and Company announced the opening of the Lilly Seaport Innovation Center (LSC) in New York City. The center serves as the central hub for Lilly's genetic medicines efforts and houses the first East Coast Lilly Center for Drug Design and Development (C4D).
Innovative Partnerships and Therapies
LSC will drive innovation through collaborations with leading academic and medical institutions, fostering a vibrant ecosystem for research and development. By combining Lilly's expertise in genetic medicines with the innovation hub of New York City, the center will accelerate the discovery and delivery of transformative therapies.
Clinical Research Advancements
The center will also be the site of clinical research for new genetic medicines. Lilly's PNT2001 and Bayer's BAY 3563254, two novel clinical radioligands for prostate cancer imaging, will be tested at LSC in PSMA-positive metastatic castration-resistant prostate cancer patients.
Conclusion:
The opening of the Lilly Seaport Innovation Center marks a significant milestone in the fight against disease. By pushing the boundaries of science and collaborating with global partners, Lilly is empowering the next generation of researchers and advancing the promise of personalized medicine. This center will not only contribute to the development of cutting-edge therapies but also strengthen Lilly's commitment to improving patients' lives worldwide.
تعليقات